AstraZeneca Announce 15% Sales Drop

AstraZeneca have announced a dip of 15% for their Q3 sales, mainly as a result of the loss of exclusivity on several key brands, and costs relating to the disposal of their former Astra Tech and Aptium Oncology units. The Anglo-Swedish organisation’s revenue fell to $6.8 million in comparison to quarter 3 in 2011.  Antipsychotic

Continue Reading

Depression Up 11.5% Over 3 Years

The number of people suffering from depression in England has grown by almost half a million in just three years, according to a new report by SSentif Intelligence. Analysing the data from the NHS Quality Outcomes Framework, the group discovered that the number of registered patients with depression increased by 11.5% from 2008 to 2011,

Continue Reading

Collaboration Best for Stretched NHS Budgets

The Association of the British Pharmaceutical Industry (ABPI) head has noted that he understands that the UK National Health Service must save money, but wishes to create new partnerships to help this happen. Stephen Whitehead, chief executive of the ABPI, writing in the Guardian’s professional network, commented that “within the changing NHS landscape, it is

Continue Reading

HRT Reduces Heart Attack Risk

The dispute around the safety and benefits of taking HRT (hormone replace therapy) has taken another turn, after a study found that long-term use of the therapy considerably reduced heart attacks and heart failure, without raising the danger of cancer, blood clots or stroke. In the study, which was published in the British Medical Journal,

Continue Reading

Progenics Makes Further Job Cuts

Progenics Pharmaceuticals are laying off more than a quarter of their workforce after failing to gain extended approval for their constipation drug, Relistor. The organisation noted that they are ending several early-stage research projects in order to concentrate on their cancer programmes, in particular a Phase II study of PSMA ADC, a human monoclonal antibody-drug

Continue Reading

J&J Resolves ADHD Lawsuit with Impax Labs and Teva

Johnson & Johnson (J&J) have established a new deal to settle a patent disagreement regarding their attention-deficit hyperactivity disorder (ADHD) drug, Concerta. Impax Laboratories and partner Teva Pharmaceutical Industries launched a lawsuit against Johnson & Johnson’s Janssen Pharmaceuticals and Alza Corp units.  Impax Laboratories announced on Friday that the lawsuit has now been settled after

Continue Reading